News

October 22, 2024 Matisse Pharmaceuticals appoints Prof. Carolyn Calfee to the Scientific Board Read more January 30, 2024 Matisse Pharmaceuticals meets primary objectives in study with M6229 in critically ill sepsis patients. Read more January 4, 2024 Matisse Pharmaceuticals closes EUR 3.6 million financing round Read more January 2, 2024 Matisse Pharmaceuticals appoints Marcel Jacobs as CEO Read more May 23, 2023 Matisse Pharmaceuticals strengthens Scientific Advisory Board with Prof. John Marshall and Prof. Mervyn Singer Read more February 9, 2023 Matisse Pharmaceuticals appoints Kees Groen and Marcel Jacobs to Board of Directors and Management Board. Read more September 7, 2022 Matisse Pharmaceuticals about to start third dose level in a Phase I/IIa study with its lead compound M6229 in septic patients. Read more November 10, 2021 Approval from the Dutch Health Authorities to initiate a Phase I study with Matisse Pharmaceuticals' lead compound M6229 in sepsis. Read more March 1, 2020 Matisse Pharmaceuticals raises financing for its phase I/IIa clinical trial treating patients suffering from sepsis. Read more